Trial 0C-20-10


A Phase 1b/2, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib (AMG 510) in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101)

Type: Treatment
Phase: Phase I/II
Status: Open to Accrual
Treatments: Other
Randomized: No
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Anthony El-Khoueiry, M.D.
Other Trial Staff:  Yan Ning, D.M., Lorraine Martinez, D.M., Charlean Ketchens, Coordinator, Jiayi Jiang, D.M., Raluca Agafitei, Coordinator, Xiomara Menendez, Coordinator, Noureddine Miloud, D.M., Jessica Levano, Coordinator, Arthur Alvarez, D.M., Khatchik Karakozian, D.M., Yanli Wang, D.M., Rabia Rehman, Coordinator, Negeen Izadian, Coordinator, Raian Fahim, D.M., Cristina Lee, Coordinator, Diane Habib, Coordinator, Angela Smith Bryant, Coordinator, Clara Karam, D.M., Judy Smith, Coordinator, Judy Smith, Coordinator, Judy Smith, Coordinator, Stephanie Kim, Coordinator, Maura Fernandez, D.M., Eva Ritzmann, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.